Magnesium drugs in therapy of pregnant women with undifferentiated connecntive tissue dysplasia

Abstract

Aim: a comprehensive study of the pathology manifestations and efficiency of magnesium therapy in pregnant women with undifferentiated connective tissue dysplasia.
 Material and Subjects: the research object was 380 women who were treated in Tula regional perinatal centre and Maternity hospital №1 of Tula with signs of undifferentiated connective tissue dysplasia during 2008-2010 yy., and as a comparison group 45 women in the absence of signs of dysplasia in the same time period. To assess the magnesium therapy effectiveness of the women experimental group they were divided into two subgroups (190+190) depending on the use/non-use of the preparation of magnesium with early pregnancy term.
 Results: undifferentiated connective tissue dysplasia during pregnancy was clinically manifested by neurocirculatory dystonia, vascular disorders and hemorrhagic syndrome, as well as a high frequency of placenta insufficiency, threatened abortion in 1-3 trimesters, isthmic-cervical insufficiency, early toxicosis and anemia of pregnant.
 The etiological-pathogenetical treatment was resulted in to the improvement of pregnant women health, reduction of the frequency of different complaints and decreased of average weight of these pregnancy complications. Normalization
 of parameters of oxyproline and magnesium in the blood of pregnant women in 12-22-34 weeks of pregnancy due to magnesium therapy was laboratory confirmed.
 Conclusion: undifferentiated connective tissue dysplasia during pregnancy contributes to the development of certain pathological conditions of various systems of the body and it can be effectively corrected by magnesium drugs (Magne-B6) under the control of oxyproline and magnesium in the blood of pregnant women.